How To Develop A Patient-First Strategy For CGT Commercialization
A patient centric approach to a complex treatment journey
Executive Summary
Many new drug commercialization decisions need to happen early in the clinical development of a therapy, and cell and gene treatments are no different. As Amerisource Bergen’s Lung-I Cheng tells In Vivo, creating a patient-first blueprint is the best place to start.
You may also be interested in...
Coming Of Age: Pharma’s Influencer Marketing Matures
Influencer marketing has emerged as a potent tool for many industries and is a sector set to be worth $22bn in its own right by 2025.
Building Out A Blockbuster Franchise: AstraZeneca’s Growth Plans For US Lung Cancer Therapy
Arun Krishna reveals portfolio plans for best-selling therapy Tagrisso, and its other activities to prevent, screen and diagnose lung cancer faster.
Investment And Acquisition In Rare Diseases
In Vivo talks to investors, analysts and companies in rare disease about the challenges they face to innovate and to grow.